{
    "ticker": "AKBA",
    "name": "Akebia Therapeutics, Inc.",
    "description": "Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with kidney disease. Founded in 2014 and based in Cambridge, Massachusetts, Akebia aims to address the unmet needs of patients suffering from chronic kidney disease (CKD) through the development of novel therapeutics targeting anemia associated with CKD. The company's lead product candidate, vadadustat, is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that is designed to treat anemia in adult patients on dialysis and those not on dialysis due to CKD. Akebia's mission is to improve the lives of patients with kidney disease and empower them with treatment options that enhance their overall health and well-being. With a robust pipeline of products and a commitment to scientific research, Akebia is poised to make significant advancements in the treatment of renal disorders. The company actively collaborates with healthcare professionals and organizations to bring effective treatments to market and support the kidney disease community.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2014",
    "website": "https://www.akebia.com",
    "ceo": "John P. Butler",
    "social_media": {
        "twitter": "https://twitter.com/AkebiaTx",
        "linkedin": "https://www.linkedin.com/company/akebia-therapeutics/"
    },
    "investor_relations": "https://investors.akebia.com",
    "key_executives": [
        {
            "name": "John P. Butler",
            "position": "CEO"
        },
        {
            "name": "Adam K. Karp",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Vadadustat"
            ]
        }
    ],
    "seo": {
        "meta_title": "Akebia Therapeutics, Inc. | Innovating Kidney Disease Treatments",
        "meta_description": "Learn about Akebia Therapeutics, Inc., a leader in developing therapies for kidney disease. Explore our commitment to improving patient outcomes and our innovative product pipeline.",
        "keywords": [
            "Akebia",
            "Kidney Disease",
            "Anemia",
            "Vadadustat",
            "Biopharmaceuticals",
            "Chronic Kidney Disease"
        ]
    },
    "faq": [
        {
            "question": "What does Akebia Therapeutics focus on?",
            "answer": "Akebia Therapeutics focuses on developing innovative therapies for patients with chronic kidney disease."
        },
        {
            "question": "Who is the CEO of Akebia Therapeutics?",
            "answer": "John P. Butler is the CEO of Akebia Therapeutics, Inc."
        },
        {
            "question": "Where is Akebia headquartered?",
            "answer": "Akebia is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is Akebia's lead product candidate?",
            "answer": "Akebia's lead product candidate is vadadustat, which is designed to treat anemia associated with chronic kidney disease."
        },
        {
            "question": "When was Akebia Therapeutics founded?",
            "answer": "Akebia Therapeutics was founded in 2014."
        }
    ],
    "competitors": [
        "AMGN",
        "RDN",
        "BMY",
        "JNJ"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "REGN",
        "BIIB"
    ]
}